Nasonex (Mometasone Furoate)

Mometasone furoate is a potent glucocorticoid that binds to intracellular glucocorticoid receptors in the nasal mucosa. This binding alters gene expression, suppressing the production of inflammatory cytokines and decreasing activation of inflammatory cells, which leads to reduced swelling and irritation of the nasal passages.

The dosing regimen for Nasonex is individualized by a qualified prescriber based on the patient’s age, condition severity and response to therapy. Typical adult dosing may involve one or two sprays per nostril once daily, but the exact number of sprays and frequency should follow the healthcare professional’s instructions.

Safety data for Nasonex in pregnancy and lactation are limited. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss potential risks and benefits with their healthcare provider before using the product, as the prescriber may decide to continue, adjust, or discontinue therapy.

To order Nasonex, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Nasonex (mometasone furoate) is a high‑potency intranasal corticosteroid with a low systemic bioavailability, similar to other agents such as fluticasone propionate and budesonide. Clinical studies suggest comparable efficacy in controlling allergic rhinitis symptoms, while its once‑daily dosing and favorable safety profile make it a convenient option for many patients.

Nasonex should be stored at room temperature, below 25 °C, in its original packaging to protect it from moisture and direct sunlight. Keep the bottle tightly closed when not in use and avoid freezing. Do not use the product after the expiration date printed on the label.

Nasonex is administered as a nasal spray. The user should gently blow the nose, tilt the head slightly forward, insert the nozzle into one nostril, close the opposite nostril with a finger, and spray the prescribed number of actuations while breathing in gently. The process is repeated for the other nostril if directed by the prescriber.

Serious adverse events, although rare, include nasal septal perforation, severe allergic reactions such as anaphylaxis, visual disturbances (including cataracts), adrenal suppression with prolonged high‑dose use, and opportunistic fungal infections of the nasal cavity. Patients should seek immediate medical attention if they experience any of these symptoms.

Nasonex should be avoided in individuals with known hypersensitivity to mometasone furoate or any component of the formulation. It is also contraindicated in patients with active untreated nasal infections, recent nasal surgery or trauma, and in those for whom systemic corticosteroid therapy is contraindicated without prior medical evaluation.